共 228 条
[1]
Chen W(2016)Cancer statistics in China 2015 CA Cancer J Clin 66 115-132
[2]
Zheng R(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[3]
Baade PD(2013)Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer Clin Oncol 31 3987-3996
[4]
Zhang S(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388
[5]
Zeng H(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 23-46
[6]
Bray F(2019)SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p Biomed Pharmacother 116 1089-938
[7]
Siegel RL(2014)Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Mol Med Rep 10 931-840
[8]
Miller KD(2019)Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer Expert Rev Clin Pharmacol 12 831-659
[9]
Jemal A(2014)Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer Clin Oncol 5 646-2614
[10]
Gainor JF(2019)Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC) Int J Biol Sci 15 2607-15